Overview of Flamic (Diclofenac)

Property	Description
Active ingredient	Diclofenac (as sodium or potassium salt)
Form	Versatile (tablets, injections, topical gels, suppositories, etc.)
Pharmacological class	Non-steroidal Anti-inflammatory Drug (NSAID)
General purpose	Pain relief, inflammation reduction, fever reduction
Origin	Synthetic, Phenylacetic acid derivative

The Identity of Flamic: Classification and Active Ingredient

Flamic (Diclofenac) is a medication whose active component, diclofenac, classifies it as a Non-steroidal Anti-inflammatory Drug (NSAID). This pharmacological categorization defines its core function as modulating the body's inflammatory response. The substance, a synthetic compound derived from phenylacetic acid, is often prepared as a salt, such as diclofenac sodium or potassium, to ensure formulation stability and efficacy. The medication is considered a potent agent in this class and acts as a reference standard in anti-inflammatory therapy. It is fundamentally a single-agent product, relying on the action of diclofenac alone.

Flamic's Core Purpose and Therapeutic Role

The primary therapeutic role of Flamic is the reliable management of pain, inflammation, and accompanying fever. The medication operates by inhibiting the synthesis of prostaglandins, which are key chemical messengers that initiate both pain signals and swelling. The substance functions as a potent analgesic and anti-inflammatory agent. This indicates that the medicine helps ease discomfort by actively reducing the biological processes that cause tissue irritation. The overall benefit is improved comfort and function, often employed in situations requiring the reduction of stiffness or swelling following intensive physical activity or general inflammatory processes.

Available Forms and Composition Type

Diclofenac is recognized for being available in a broad spectrum of pharmaceutical forms to enable both systemic and highly localized application. These high-level dosage forms include oral tablets, injectable solutions, and preparations for application directly to the skin, such as topical gels and patches. This versatility in forms, including oral, intramuscular, or topical routes of administration, ensures that the active ingredient can be effectively delivered to the body. The different delivery systems utilize various pharmaceutical bases, such as aqueous solutions for injections or specialized hydroalcoholic gels for dermal use, to maximize the substance's effect where it is needed most.

What side effects are possible with Flamic (Diclofenac)?

Possible side effects and safety information

Flamic (Diclofenac) carries documented risks for serious, potentially fatal, cardiovascular and gastrointestinal adverse events, as highlighted by regulatory authorities. The risk of major events, such as Myocardial Infarction (MI) and Stroke, may increase with higher doses and longer duration of use. Similarly, the risk of serious Gastrointestinal (GI) adverse events (e.g., bleeding, ulceration, or perforation of the stomach or intestines) increases with dose and exposure time.

Serious and Clinically Significant Adverse Reactions

Cardiovascular Thrombotic Events: Risk of serious events including MI and stroke, which can occur at any time, with or without warning symptoms. The drug is contraindicated for the treatment of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.
Gastrointestinal Adverse Events: Risk of fatal GI inflammation, bleeding, ulceration, or perforation. Older patients are at a greater risk for these events.
Hepatotoxicity: Risk of serious liver injury, including fatal fulminant hepatitis, liver necrosis, and hepatic failure, though this is reported as very rare.
Hypersensitivity and Skin Reactions: Serious skin reactions, such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, are reported very rarely. Anaphylactic/Anaphylactoid reactions can occur.
Renal Toxicity: Risk of new-onset or worsening renal dysfunction, fluid retention, and edema; this requires monitoring in patients with pre-existing conditions.

Contraindications and Risk Limitation

The medicine is contraindicated in patients with a history of aspirin-sensitive asthma, severe uncontrolled heart failure (NYHA Class II-IV), established Ischaemic Heart Disease, Peripheral Arterial Disease, Cerebrovascular Disease, or in the last trimester of pregnancy due to risk of premature closure of the fetal ductus arteriosus. To minimize documented risks, regulatory guidance requires the use of the lowest effective dose for the shortest duration possible.

Overdose and Emergency Response

In cases of suspected Flamic (Diclofenac) overdosage, regulatory documents mandate that emergency medical help be sought immediately. The official overdose profile indicates that while many patients may remain asymptomatic or experience only minor gastrointestinal discomfort, severe and potentially life-threatening outcomes are documented, requiring urgent medical evaluation.

Documented Manifestations and Severe Outcomes

System	Documented Signs/Symptoms
Gastrointestinal	Nausea, vomiting, stomach pain, GI bleeding (e.g., bloody stools)
Central Nervous System	Drowsiness, dizziness, tinnitus, lack of energy
Severe Outcomes	Seizures, loss of consciousness, acute renal failure, hepatic failure, coma

Official Management and Risk Notes

The documented management approach is limited to symptomatic and supportive treatment, as no specific antidote is known. The official labeling notes that activated charcoal and an osmotic cathartic may be considered within four hours of ingestion for symptomatic patients with a large overdose. Procedures such as forced diuresis or hemodialysis are generally not expected to be effective due to the drug's high protein binding.

Regulatory documents highlight that elderly patients and individuals with advanced renal or severe heart failure are documented to be at increased risk for serious complications following an overdose event. Immediate discontinuation of the drug is required if severe symptoms occur.

Therapeutic Uses of Flamic (Diclofenac)

What Flamic (Diclofenac) Treats: Main Uses and Benefits

Flamic is commonly used in situations involving certain distressing symptoms across domains where additional symptomatic support is needed. The medication is applied in addressing conditions where functional stability becomes affected by discomfort and systemic stress.

The medication offers symptomatic relief that helps patients cope more steadily with conditions presenting with acute episodes or recurrent manifestations. It is commonly used to help with symptoms related to inflammatory or irritative states, symptoms related to physical discomfort, and symptoms associated with acute or episodic changes.

It is commonly applied in clinical settings that involve acute or unstable symptom patterns. It is relevant when supportive symptom management is appropriate, assisting with maintaining functional stability and supporting the patient during difficult episodes by easing distress.

Quick Fact: Relief for Physical Discomfort Flamic provides support that helps ease the overall symptom burden in conditions marked by increased discomfort or tension.

Regulatory References

National Institutes of Health MedlinePlus Drug Information overview

Eligibility and Restrictions for Use

Flamic (Diclofenac), as an NSAID, carries strict regulatory exclusions that define its eligible user base, as detailed in official government prescribing information.

Contraindicated Populations (Must Not Use)

Systemic use of diclofenac is strictly contraindicated in patients with established severe cardiovascular disease, including Ischaemic Heart Disease, Cerebrovascular Disease, Peripheral Arterial Disease, and Congestive Heart Failure (NYHA class II–IV). It is also prohibited for patients with a known hypersensitivity to diclofenac, a history of asthma, urticaria, or other allergic reactions precipitated by aspirin or other NSAIDs, and during the last trimester of pregnancy (from 30 weeks gestation) [2.2, 1.4]. Absolute contraindications also include patients with active gastrointestinal ulceration, bleeding, or perforation, and those undergoing peri-operative pain management for Coronary Artery Bypass Graft (CABG) surgery [1.1].

Age and Condition-Based Restrictions

Pediatric Use: Safety and efficacy are generally not established for children under 12 years of age for many systemic forms. High-strength oral forms are not recommended for children and adolescents under 14 years [1.1].
Pregnancy Status: Use between 20 and 30 weeks gestation must be limited and requires monitoring due to the risk of fetal renal dysfunction [1.8]. For breastfeeding, most regulatory guidance notes the excretion of low amounts into milk and advises weighing potential benefits against potential risks to the infant [3.3].
Organ Impairment: The medication is contraindicated in patients with severe hepatic failure or severe renal impairment. Caution is required, and monitoring of renal function is advised, for patients with mild-to-moderate renal or hepatic impairment [4.1].
Geriatric Patients: Older adults are generally eligible, but caution is advised due to a higher susceptibility to adverse reactions, requiring the lowest effective dose for the shortest possible duration [1.2, 2.4].

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory profile for Flamic (Diclofenac) highlights several officially documented interaction patterns that influence safety and efficacy.

Contraindicated Combinations and Procedural Constraints

Use is contraindicated in patients with a history of allergic-type reactions to aspirin or other Non-steroidal Anti-inflammatory Drugs (NSAIDs), such as asthma or urticaria. Furthermore, the use of Diclofenac is prohibited in the perioperative setting of Coronary Artery Bypass Graft (CABG) surgery.

Pharmacodynamic and Exposure Interactions

Anticoagulants and antiplatelet agents (including certain doses of aspirin) are documented to have an additive risk of serious gastrointestinal bleeding when co-administered.

Diclofenac can officially diminish the therapeutic effects of certain antihypertensive medicines (such as ACE Inhibitors and ARBs) and diuretics. Co-administration is also documented to increase the plasma concentrations and potential toxicity risk of agents such as Methotrexate, Lithium, and Digoxin.

Pharmacokinetic interaction exists with strong enzyme inhibitors like Voriconazole, which is documented to significantly increase the plasma exposure (AUC and Cmax) of Diclofenac. The risk of renal function deterioration with ACE Inhibitors or ARBs is noted as higher in elderly or volume-depleted patients.

For certain specific oral formulations, taking the medicine with food is documented to cause a reduction in effectiveness.

Mechanism of Action

The mechanism of action for Diclofenac involves its molecular activity, which modulates specific physiological signaling pathways. The drug is primarily an inhibitor of the cyclooxygenase (COX) enzymes, an action that produces its resulting physiological outcomes.

Inhibition of Prostanoid Synthesis

Diclofenac works by competitively binding to and inhibiting both the constitutive COX-1 and inducible COX-2 enzymes, though it exhibits a preferential selectivity for COX-2. This primary action reduces the conversion of the precursor, arachidonic acid, into pro-inflammatory mediators, chiefly prostaglandin E2 (PGE2). This molecular modification results in the systemic reduction of the chemical signals that modulate localized vascular permeability and nociceptor sensitivity at the peripheral level.

Modulation of Nociceptive and Thermal Signaling

The reduction of PGE2 concentration prevents the sensitization of peripheral nociceptors (pain nerve endings), which decreases the excitability of afferent neuronal signaling to the central nervous system. This mechanistic step contributes to the physiological mechanism of antinociception. Furthermore, the drug's action extends centrally to the hypothalamus, where reduced prostaglandin levels prevent the neurochemical elevation of the body's thermal set point, a mechanism that modulates the core body temperature.

Dosage and Administration Information

Flamic (Diclofenac) is administered via multiple official pathways, encompassing oral forms (tablets, capsules, powder for solution), topical applications (gels), and parenteral routes (intramuscular and intravenous injection). This versatility allows for both systemic and local administration of the active ingredient. Systemic use typically follows a total daily dose ranging from 100 mg to 150 mg, with a general maximum recommended daily dose of 150 mg for most adult indications. The medication is commonly taken in divided doses (two to four times daily) to maintain consistent levels, while some extended-release forms are approved for once-daily administration.

The manner in which the medicine is taken is specified in official labeling. Delayed-release (enteric-coated) tablets must be swallowed whole and should not be crushed or chewed, a condition necessary to preserve their release properties. For specific, rapid-onset uses, such as the powder for oral solution, the instructions require mixing with water and immediate consumption on an empty stomach. Parenteral administration, performed in a supervised setting, is generally restricted to a maximum duration of two days, necessitating a transition to oral or rectal dosage forms thereafter. For certain populations, such as older adults, official instructions specify that treatment must commence at the lowest effective dosage for the shortest duration necessary.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Clinical Research

Studies focused on the compound's potential association with reducing pain and improving mobility. Initial preclinical and small human studies focused on characterizing the biological pathways that the compound engages. Following these early findings, larger, randomized studies were initiated.

Pain and Mobility Outcomes

Studies evaluated whether this combination was associated with changes in both pain and mobility across various demographics. A major focus of the research was on quantifying changes in patient-reported pain scores (e.g., using a Visual Analog Scale) and objective measures of joint function.

Primary Studies: The body of evidence primarily consists of 12 randomized, placebo-controlled trials. The duration of these trials ranged from 4 to 12 weeks. Participants generally had moderate to severe symptoms of the target condition.
Long-Term Follow-up: The largest study to date reported on the drug’s potential effect on symptom severity over time. In this study, participants were monitored for up to 6 months after the initial treatment period. Findings from this follow-up reported on observations during the post-treatment period.

Safety and Time Course of Reported Changes

Clinical trials documented the time course of reported observations, noting initial changes and the timeframe for the largest magnitude of reported changes.

Small-scale studies have examined the safety profile during long-term use, including among older adults. These studies assessed the frequency and severity of adverse events associated with prolonged administration.

Conclusion of Evidence

Overall, the evidence remains under review regarding whether the drug is associated with reduced pain in this condition. This approach has been the subject of research. The preceding information summarizes the existing clinical evidence.

Frequently Asked Questions (FAQ)

Common questions about Flamic (Diclofenac) (FAQ)

Q: How quickly should I expect Flamic to start working after I take it?

According to official product information, the time it takes for Diclofenac to reach its maximum concentration in the blood varies significantly based on the specific type of tablet used. While rapid-acting formulations may start to work faster, some delayed-release tablets might take two hours or more to reach their maximum concentration, depending on the formulation.

Q: What is the longest time Flamic's pain relief typically lasts?

The expected duration of action is inferred from the recommended dosing frequency. Many formulations of Diclofenac are often recommended to be taken in divided doses, such as two to four times daily. This schedule suggests the period of effect may last several hours, but individual response to the medication can vary.

Q: What is the purpose of the enteric coating on some Diclofenac tablets?

Official information explains that delayed-release (enteric-coated) tablets are designed to resist breakdown in the stomach. This special coating allows the medicine to be released further down in the intestines. This process helps to both preserve the tablet's effectiveness and minimize direct irritation to the lining of the stomach.

Q: Can Flamic be crushed or chewed?

Regulatory instructions state that delayed-release, enteric-coated, and extended-release tablets should be swallowed whole. Crushing, breaking, or chewing these specific types of tablets should be avoided, as doing so would compromise the intended release properties of the medication.

Q: Why is it important to take Flamic with food or milk?

Taking oral Diclofenac along with food, milk, or a snack is a recommendation often included in official patient guidelines. This practice is specifically intended to help minimize or reduce the potential for gastrointestinal side effects, such as stomach upset and irritation, which are associated with this class of medication.

Q: Is it normal to experience mild headaches when starting Flamic?

Official regulatory documents list headaches and dizziness among the adverse reactions reported with the use of oral Diclofenac. These are often included in the categories of more common or frequently reported non-serious side effects that patients may experience.

Q: Can Flamic cause fluid retention or swelling?

Yes, regulatory warnings state that Non-steroidal Anti-inflammatory Drugs (NSAIDs), including Flamic, can cause fluid retention and swelling, also known as edema. This effect is why the medication requires caution in patients with pre-existing conditions like high blood pressure or heart failure, as it could potentially worsen these issues.

Q: Are there different forms of Flamic available (e.g., gel, tablets, patches)?

According to official product information, the active ingredient Diclofenac is available in a variety of regulatory-approved dosage forms. These delivery systems include oral tablets, capsules, injectable solutions, and preparations for topical application, such as gels and patches.

Q: Can Flamic be used for period pain relief?

Regulatory information indicates that certain formulations of Diclofenac, particularly those that are designed for rapid absorption, are specifically indicated for the relief of mild to moderate acute pain. This established indication may apply to conditions such as primary dysmenorrhea (period pain), depending on the specific formulation and regulatory approval.

Q: Do people commonly use Flamic for general back pain?

Diclofenac is generally indicated in official labeling for relieving the signs and symptoms of acute and chronic painful, inflammatory conditions. Back pain resulting from underlying inflammatory conditions like arthritis may be addressed under these established indications, especially when the pain is related to inflammation.

Q: Does alcohol consumption affect how Flamic works or increase its side effects?

Regulatory documents indicate that alcohol use is a factor that may heighten the risk of serious gastrointestinal adverse events, such as bleeding or ulceration, when taking NSAIDs like Diclofenac.

Q: Is Flamic safe for use by older adults?

Regulatory guidelines state that older adults are eligible, but are generally advised to use caution due to an increased risk for serious adverse reactions, especially gastrointestinal bleeding. Official guidance emphasizes that treatment should commence at the lowest effective dose for the shortest possible duration.

Q: Does Flamic affect blood sugar levels in people with diabetes?

Official documents advise that when Diclofenac is used concurrently with certain anti-diabetic medications, there have been reports of changes in blood sugar. These changes include both hypoglycemia (low blood sugar) and hyperglycemia (high blood sugar), and monitoring may be required.

Q: Does using a Flamic patch or gel have any systemic effects?

Yes, even when applied topically as a gel or patch, Diclofenac is absorbed and enters the bloodstream, leading to systemic exposure. The lower systemic exposure is associated with a reduced potential for systemic adverse effects compared to oral forms, according to official studies.

Q: Is Flamic a common prescription for arthritis pain?

Yes, Diclofenac is officially indicated in regulatory labeling for the relief of the signs and symptoms of various inflammatory joint conditions. These established indications include both osteoarthritis and rheumatoid arthritis.

Q: Can Flamic be used for dental pain after a procedure?

Some formulations of Diclofenac are specifically indicated for the relief of mild to moderate acute pain. This broad indication in regulatory documents may include acute, short-term pain, such as that sometimes associated with dental procedures.

Q: Why is Flamic sometimes prescribed for gout flare-ups?

Diclofenac is officially indicated for the treatment of various inflammatory conditions. Specifically, regulatory documents confirm its use for the acute or short-term treatment of inflammatory joint diseases like acute gouty arthritis.

Q: Can Flamic cause skin sensitivity to the sun?

Yes, official regulatory labeling lists photosensitivity, which is an increased skin sensitivity to natural or artificial sunlight, as an adverse reaction associated with Diclofenac. Official labeling often advises protecting treated areas from natural or artificial sunlight, particularly when using topical forms.

Q: Can taking Flamic make you feel drowsy or dizzy?

Yes, official regulatory documents list both dizziness and drowsiness among the common adverse reactions reported with Diclofenac use. This potential side effect is why caution regarding activities like driving or operating machinery is often advised.

Q: What happens if I accidentally take two doses of Flamic too close together?

Regulatory patient information states that if a dose is forgotten, it can be taken as soon as remembered unless it is nearly time for the next scheduled dose. Official information advises against taking two doses together to make up for a forgotten one, which helps prevent taking too much medication.

Q: Are there known interactions between Flamic and common antidepressants?

Yes, regulatory documents mention a known interaction with Selective Serotonin Reuptake Inhibitors (SSRIs), which is a common class of antidepressants. Concurrent use with SSRIs increases the documented risk of serious gastrointestinal bleeding.

Q: What should I do if I forget to take my scheduled dose of Flamic?

Official instructions generally state that if a dose is missed, it can be taken as soon as it is remembered, unless it is nearly time for the next scheduled dose. If it is nearly time for the next dose, the missed dose should be skipped entirely to prevent taking doses too close together.

Q: How is the dose of Flamic usually decided by a doctor?

Official guidance requires that the lowest effective dose be used for the shortest duration necessary for all patients. Official guidance emphasizes that dosing should be determined by a healthcare provider based on the individual's treatment goals while prioritizing the minimization of potential risk for cardiovascular and gastrointestinal adverse events.

Q: Are there any warning signs I should look for when taking Flamic?

Official labeling instructs patients to look for and report signs of serious adverse reactions. These include signs of gastrointestinal bleeding (such as black, tarry stools or vomiting blood) and symptoms of a heart attack or stroke (such as chest pain or sudden weakness).

Q: Is it safe to switch from one brand of Diclofenac to Flamic?

Regulatory documents explicitly warn that different dose strengths and formulations of oral Diclofenac are not interchangeable across brands. Due to these documented differences, any change in formulation or brand generally requires the review of a healthcare provider.

How should Flamic (Diclofenac) be stored and disposed of?

Official Storage and Disposal Requirements

Storage Conditions

Requirement	Official Instruction
Temperature	Store at room temperature, typically between 15 C and 30 C (USP Controlled Room Temperature), or as specifically directed below 25 C.
Protection	Keep the medicine in its original, tightly closed container and protect it from excessive moisture and light.
Safety	Keep the medication out of the sight and reach of children.
Handling	For topical forms, avoid applying external heat or occlusive dressings to the treated area, and protect the area from natural or artificial sunlight.

Disposal Requirements

To dispose of unused or expired Diclofenac, follow official disposal instructions from regulatory labeling or consult local drug take-back programs. Due to environmental risks, specifically its aquatic toxicity, official documents caution against improper disposal. The drug must not be released into the environment, including avoiding flushing it down the toilet or pouring it into water courses unless explicitly instructed otherwise.

Flamic (Diclofenac)